|
1
|
Taylor LP: Diagnosis, treatment, and
prognosis of glioma: Five new things. Neurology. 75(Suppl 1):
S28–S32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brada M, Stenning S, Gabe R, Thompson LC,
Levy D, Rampling R, Erridge S, Saran F, Gattamaneni R, Hopkins K,
et al: Temozolomide versus procarbazine, lomustine, and vincristine
in recurrent high-grade glioma. J Clin Oncol. 28:4601–4608. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morris PG and Lassman AB: Medical
oncology: Optimizing chemotherapy and radiotherapy for anaplastic
glioma. Nat Rev Clin Oncol. 7:428–430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gabayan AJ, Green SB, Sanan A, Jenrette J,
Schultz C, Papagikos M, Tatter SP, Patel A, Amin P, Lustig R, et
al: GliaSite brachytherapy for treatment of recurrent malignant
gliomas: A retrospective multi-institutional analysis.
Neurosurgery. 58:701–709; discussion 701–709. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sciumè G, Santoni A and Bernardini G:
Chemokines and glioma: Invasion and more. J Neuroimmunol. 224:8–12.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Butowski NA, Sneed PK and Chang SM:
Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin
Oncol. 24:1273–1280. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song X, Han P, Liu J, Wang Y, Li D, He J,
Gong J, Li M, Tu W, Yan W, et al: Up-regulation of SPOCK1 induces
epithelial-mesenchymal transition and promotes migration and
invasion in esophageal squamous cell carcinoma. J Mol Histol.
46:347–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miao L, Wang Y, Xia H, Yao C, Cai H and
Song Y: SPOCK1 is a novel transforming growth factor-β target gene
that regulates lung cancer cell epithelial-mesenchymal transition.
Biochem Biophys Res Commun. 440:792–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Chen L, Chan TH, Liu M, Kong KL, Qiu
JL, Li Y, Yuan YF and Guan XY: SPOCK1 is regulated by CHD1L and
blocks apoptosis and promotes HCC cell invasiveness and metastasis
in mice. Gastroenterology. 144:179–191.e4. 2013. View Article : Google Scholar
|
|
10
|
Shu YJ, Weng H, Ye YY, Hu YP, Bao RF, Cao
Y, Wang XA, Zhang F, Xiang SS, Li HF, et al: SPOCK1 as a potential
cancer prognostic marker promotes the proliferation and metastasis
of gallbladder cancer cells by activating the PI3K/AKT pathway. Mol
Cancer. 14:122015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Colin C, Baeza N, Bartoli C, Fina F, Eudes
N, Nanni I, Martin PM, Ouafik L and Figarella-Branger D:
Identification of genes differentially expressed in glioblastoma
versus pilocytic astrocytoma using suppression subtractive
hybridization. Oncogene. 25:2818–2826. 2006. View Article : Google Scholar
|
|
12
|
Taillibert S, Pedretti M and Sanson M:
Current classification of gliomas. Presse Med. 33:1274–1277.
2004.In French. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beetz C, Bergner S, Brodoehl S, Brodhun M,
Ewald C, Kalff R, Krüger J, Patt S, Kiehntopf M and Deufel T:
Outcome-based profiling of astrocytic tumours identifies prognostic
gene expression signatures which link molecular and
morphology-based pathology. Int J Oncol. 29:1183–1191.
2006.PubMed/NCBI
|
|
14
|
Kayaselçuk F, Zorludemir S, Gümürdühü D,
Zeren H and Erman T: PCNA and Ki-67 in central nervous system
tumors: Correlation with the histological type and grade. J
Neurooncol. 57:115–121. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Punchihewa C, Inoue A, Hishiki A, Fujikawa
Y, Connelly M, Evison B, Shao Y, Heath R, Kuraoka I, Rodrigues P,
et al: Identification of small molecule proliferating cell nuclear
antigen (PCNA) inhibitor that disrupts interactions with PIP-box
proteins and inhibits DNA replication. J Biol Chem.
287:14289–14300. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Alderson LM, Castleberg RL, Harsh GR IV,
Louis DN and Henson JW: Human gliomas with wild-type p53 express
bcl-2. Cancer Res. 55:999–1001. 1995.PubMed/NCBI
|
|
17
|
Deckert-Schlüter M, Rang A and Wiestler
OD: Apoptosis and apoptosis-related gene products in primary
non-Hodgkin's lymphoma of the central nervous system. Acta
Neuropathol. 96:157–162. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rossé T, Olivier R, Monney L, Rager M,
Conus S, Fellay I, Jansen B and Borner C: Bcl-2 prolongs cell
survival after Bax-induced release of cytochrome c. Nature.
391:496–499. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Borner C: The Bcl-2 protein family:
Sensors and checkpoints for life-or-death decisions. Mol Immunol.
39:615–647. 2003. View Article : Google Scholar
|
|
20
|
Porter AG and Jänicke RU: Emerging roles
of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lin C, Holland RE Jr, Donofrio JC, McCoy
MH, Tudor LR and Chambers TM: Caspase activation in equine
influenza virus induced apoptotic cell death. Vet Microbiol.
84:357–365. 2002. View Article : Google Scholar
|
|
22
|
Brown GT and Murray GI: Current
mechanistic insights into the roles of matrix metalloproteinases in
tumour invasion and metastasis. J Pathol. 237:273–281. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sawaya RE, Yamamoto M, Gokaslan ZL, Wang
SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG,
Nicolson GL and Rao JS: Expression and localization of 72 kDa type
IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp
Metastasis. 14:35–42. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rao JS, Steck PA, Mohanam S,
Stetler-Stevenson WG, Liotta LA and Sawaya R: Elevated levels of
M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res.
53(Suppl): 2208–2211. 1993.PubMed/NCBI
|
|
25
|
Forsyth PA, Wong H, Laing TD, Rewcastle
NB, Morris DG, Muzik H, Leco KJ, Johnston RN, Brasher PM,
Sutherland G, et al: Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and
membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in
different aspects of the pathophysiology of malignant gliomas. Br J
Cancer. 79:1828–1835. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sawaya R, Go Y, Kyritisis AP, Uhm J,
Venkaiah B, Mohanam S, Gokaslan ZL and Rao JS: Elevated levels of
Mr 92,000 type IV collagenase during tumor growth in vivo. Biochem
Biophys Res Commun. 251:632–636. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ströbele S, Schneider M, Schneele L,
Siegelin MD, Nonnenmacher L, Zhou S, Karpel-Massler G, Westhoff MA,
Halatsch ME and Debatin KM: A Potential role for the inhibition of
PI3K signaling in glioblastoma therapy. PLoS One. 10:e01316702015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiao Y, Li H, Liu Y, Guo A, Xu X, Qu X,
Wang S, Zhao J, Li Y and Cao Y: Resveratrol inhibits the invasion
of glioblastoma-initiating cells via down-regulation of the
PI3K/Akt/NF-κB signaling pathway. Nutrients. 7:4383–4402. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi L, Fei X, Wang Z and You Y: PI3K
inhibitor combined with miR-125b inhibitor sensitize TMZ-induced
anti-glioma stem cancer effects through inactivation of
Wnt/β-catenin signaling pathway. In Vitro Cell Dev Biol Anim.
51:1047–1055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Geuna E, Milani A, Martinello R, Aversa C,
Valabrega G, Scaltriti M and Montemurro F: Buparlisib, an oral
pan-PI3K inhibitor for the treatment of breast cancer. Expert Opin
Investig Drugs. 24:421–431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ku BM, Jho EH, Bae YH, Sun JM, Ahn JS,
Park K and Ahn MJ: BYL719, a selective inhibitor of
phosphoinositide 3-Kinase α, enhances the effect of selumetinib
(AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Invest New Drugs. 33:12–21. 2015. View Article : Google Scholar
|
|
32
|
Brabletz T, Herrmann K, Jung A, Faller G
and Kirchner T: Expression of nuclear beta-catenin and c-myc is
correlated with tumor size but not with proliferative activity of
colorectal adenomas. Am J Pathol. 156:865–870. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang N, Wang Y, Hui L, Li X and Jiang X:
SOX 1, contrary to SOX 2, suppresses proliferation, migration, and
invasion in human laryngeal squamous cell carcinoma by inhibiting
the Wnt/β-catenin pathway. Tumour Biol. 36:8625–8635. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee KS, Kwak Y, Nam KH, Kim DW, Kang SB,
Choe G, Kim WH and Lee HS: c-MYC Copy-Number Gain Is an Independent
Prognostic Factor in Patients with Colorectal Cancer. PLoS One.
10:e01397272015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Leone A, Roca MS, Ciardiello C,
Terranova-Barberio M, Vitagliano C, Ciliberto G, Mancini R, Di
Gennaro E, Bruzzese F and Budillon A: Vorinostat synergizes with
EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation
of the major mitochondrial porin VDAC1 and modulation of the
c-Myc-NRF2-KEAP1 pathway. Free Radic Biol Med. 89:287–299. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ouyang Q, Chen G, Zhou J, Li L, Dong Z,
Yang R, Xu L, Cui H, Xu M and Yi L: Neurotensin signaling
stimulates glioblastoma cell proliferation by upregulating c-Myc
and inhibiting miR-29b-1 and miR-129-3p. Neuro Oncol. 18:216–226.
2016. View Article : Google Scholar
|
|
37
|
Suk FM, Lin SY, Lin RJ, Hsine YH, Liao YJ,
Fang SU and Liang YC: Bortezomib inhibits Burkitt's lymphoma cell
proliferation by downregulating sumoylated hnRNP K and c-Myc
expression. Oncotarget. 6:25988–26001. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fu Q, Chen Z, Gong X, Cai Y, Chen Y, Ma X,
Zhu R and Jin J: β-Catenin expression is regulated by an
IRES-dependent mechanism and stimulated by paclitaxel in human
ovarian cancer cells. Biochem Biophys Res Commun. 461:21–27. 2015.
View Article : Google Scholar : PubMed/NCBI
|
